Quantcast
Last updated on April 21, 2014 at 4:51 EDT

Latest Management of cancer Stories

2014-01-04 23:02:32

Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, responds to an article published by MySunCoast.com that discusses a new brain cancer treatment that will specifically target glioblastomas. New York, NY (PRWEB) January 04, 2014 Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, responds to an article published by MySunCoast.com that takes a deeper look into a new brain cancer treatment that will...

2013-12-27 12:22:29

Non-profit provides tens of millions in grants since founding by Barbara and Edward Netter in 2001 STAMFORD, Conn., Dec. 27, 2013 /PRNewswire/ -- As the potential of gene and cell therapy in fighting cancers grows and oncologists across the nation explore the burgeoning science, doctors have uncovered a stunning development - cancers can be treated using patients' own cells as a weapon, and can eliminate the harrowing, often debilitating effects of chemotherapy, radiation and surgery. (Photo:...

Science Magazine Compiles Top Ten Breakthroughs Of 2013
2013-12-20 06:01:28

April Flowers for redOrbit.com - Your Universe Online At the end of each year, Science combs through the scientific breakthroughs of the past year and compiles a top ten list. This year, the list includes major breakthroughs in solar cell technologies, genome-editing techniques and vaccine design strategies, to name a few. But the number one breakthrough came in the form of cancer immunotherapy. 2013 saw a striking change in the cancer research community in the form of a strategy that...

2013-12-19 12:29:53

Recurrent lung cancer responds to Integrative Immunotherapy SCOTTSDALE, Ariz., Dec. 19, 2013 /PRNewswire/ -- Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope. To view the multimedia assets associated with this release, please click:...

2013-12-19 12:03:39

As cancer maintains its standing as the second leading cause of death in the U.S., researchers have continued their quest for safer and more effective treatments. Among the most promising advances has been the rise of nanomedicine, the application of tiny materials and devices whose sizes are measured in the billionths of a meter to detect, diagnose and treat disease. A new research review co-authored by a UCLA professor provides one of the most comprehensive assessments to date of...

2013-12-14 08:20:06

Fourth Head-to-Head Comparison Reveals Important Clinical Distinctions Between Oncotype DX, the Only Test Demonstrated to Predict Chemotherapy Benefit, and Tests Limited to Breast Cancer Prognosis REDWOOD CITY, Calif., Dec. 14, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from three studies of its Oncotype DX(®) breast cancer test presented at the 36(th) Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), reinforcing the unmatched value of the...

2013-12-13 08:25:26

NEW YORK, Dec. 13, 2013 /PRNewswire/ -- The first Esteya® electronic brachytherapy system in the United States has been installed at New York's Memorial Sloan-Kettering Cancer Center. Esteya by Nucletron, an Elekta company, is a new approach for skin cancer treatment that relies on a small, high dose rate (HDR) X-ray source to apply high precision radiotherapy directly to the cancer site. "With support from Elekta, Memorial Sloan-Kettering will lead a multicenter clinical study...

2013-12-13 08:24:48

VENTANA HER2 (4B5) IHC assay label expansion coincides with therapy availability in many non-U.S. countries globally TUCSON, Ariz., Dec. 13, 2013 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announces the VENTANA HER2/neu (4B5) Rabbit Monoclonal Primary Antibody assay as a companion diagnostic(1) for detecting HER2 protein expression for patients who, in countries where they are approved, may be appropriate candidates for Perjeta(®) (pertuzumab)...

2013-12-10 04:22:39

LONDON, December 10, 2013 /PRNewswire/ -- - A first-of-its-kind medical option for patients not able to receive existing treatments, with an emphasis on quality of life - London leads the way in this treatment approach Care Oncology Clinic (COC), an independent, private organisation providing oncology treatments, announces today the launch of its first clinic on London's Harley Street. Delivered by leading oncologists and palliative care...

2013-12-09 23:21:19

Results from an ECOG-ACRIN Cancer Research Group trial show the benefit of using the combination of docetaxel and ADT as initial treatment. Philadelphia, PA (PRWEB) December 09, 2013 Men suffering from highly advanced prostate cancer have new hope for longer survival times based on a recent clinical trial, the interim results of which were just announced by the National Institutes of Health. The findings suggest that physicians can immediately consider changing their clinical practice...